Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients with Diabetes

This meta-analysis uses data from patients with type 2 diabetes from 6 outcomes trials to investigate the association of sodium-glucose cotransporter 2 inhibitors with cardiovascular- and kidney disease–related outcomes.